research Treatment of Alopecia Areata with Simvastatin/Ezetimibe
Simvastatin/ezetimibe may help treat new cases of alopecia areata but not long-term cases.
Search
for
Sort by
Research
180-210 / 1000+ results
research Unsuccessful Treatment of Alopecia Areata with Simvastatin/Ezetimibe: Experience in 12 Patients
Simvastatin/ezetimibe did not effectively treat severe alopecia areata and caused side effects in some patients.
research Quintaquinone, a Merosesquiterpene from the Yellow Sponge Verongula cf. rigida Esper
A new compound from a sponge strongly inhibits an enzyme linked to male-pattern hair loss without being toxic at low levels.
research Multistage Transdermal Nitric Oxide Delivery System for the Efficient Treatment of Androgenic Alopecia
The new nitric oxide delivery system may effectively treat hair loss by improving hair follicle health and reducing inflammation.
research Alleviation of hyperlipidemia, insulin resistance, and myopathy by nano selenium/ nano CoQ10 platform with simvastatin in hyperlipidemic rats; comprehensive outlook
Nano selenium and CoQ10 helped reduce blood fat levels and insulin resistance while preventing muscle damage from statin drugs in rats.
research EFECTO DEL FINASTERIDE EN UN MODELO DE ISQUEMIA/REPERFUSION EN CORAZON DE RATA
Finasteride may reduce heart damage in rats.
research Hormonal manipulation with finasteride or oral contraception does not influence incidence of renal cell carcinoma
research 598 Response to ritlecitinib treatment based on salt improvement scores in patients with alopecia areata (AA): Post hoc analysis of the allegro phase 2b/3 study
Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.
research Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO ‐LT phase 3, open‐label study
Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
research Minoxidil
research Serenoa repens induced erectile dysfunction: Underdiagnosis and phytovigilance
Saw palmetto may cause erectile dysfunction and needs better safety monitoring.
research Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring
Ruxolitinib effectively and safely regrows hair in alopecia patients.
research Table 3_Computational drug discovery of potential 5α-reductase phytochemical inhibitors and hair growth promotion using in silico techniques.xlsx
Jamogenin and other molecules may help treat hair loss by inhibiting 5-alpha reductase.
research Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
research Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration’s adverse event reporting system databases
Rimegepant causes more nausea and skin issues, while ubrogepant causes more muscle issues; personalized treatment is important.
research LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1.
LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.
research Minoxidil
Minoxidil effectively treats severe hypertension but has notable side effects.
research MINOXIDIL-HAEMODYNAMIC AND CLINICAL EXPERIENCES WITH A NEW PERIPHERAL VASODILATOR
Minoxidil helps control blood pressure but has side-effects, so it's not for everyone.
research Association of prior 5-α-reductase inhibitor exposure with ICI benefit in metastatic RCC: Multicentre cohort with single-cell immune profiling.
Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.
research 5α-Reductase Inhibitors Do Not Prevent the Development and Progression of Urothelial Cancer: In Vitro Evidence
5α-reductase inhibitors don't stop bladder cancer from developing or getting worse.
research Synthesis of novel andostane-N-cyclohexyl-17-carboxamides, and their effect on the 5α-reductase isoform 2, the androgen receptor, and androgen-dependent glands
New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.
research 5α-reductase inhibitors impact prognosis of urothelial carcinoma
5α-reductase inhibitors may lower the risk of death from bladder cancer.
research Rational Design and Synthesis of 4-((1R,2R)-2-Hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a Novel, Nonsteroidal Androgen Receptor Antagonist Devoid of Phototoxicity for Dermatological Indications
PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.
research Role of 5α-reductase inhibitors in Parkinson's disease: Gambling or not?
research The Effect of Simvastatin on Plasma Steroid Hormone Levels in Metformin-Treated Women with Non-Classic Congenital Adrenal Hyperplasia
Simvastatin may help manage symptoms in women with non-classic congenital adrenal hyperplasia by lowering cholesterol and certain hormone levels.
research 43364 Long Term Real-World Patient-Reported Outcomes with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry
research Novel Synthetic Steroid Derivatives: Target Prediction and Biological Evaluation of Antiandrogenic Activity
New steroid compounds may help with hormonal therapy and have potential benefits for glucose disorders, but more research is needed.
research Discovery and Optimization of Novel Pyridines as Highly Potent and Selective Glycogen Synthase Kinase 3 Inhibitors
New pyridine compounds effectively inhibit GSK3, a diabetes treatment target.
research Reporting on Adverse Clinical Events
Certain medications can reduce mortality risk in COPD patients, but others can increase risks of cardiovascular issues, postoperative delirium, and other adverse effects.
research Association of long-term 5α-reductase inhibitor use with survival in men with renal cell carcinoma: a nationwide population-based cohort study
Long-term use of 5α-reductase inhibitors may improve survival in men with kidney cancer.